Cassini features among most promising private ophthalmology companies at Ophthalmology Innovation Summit (OIS@ASCRS) in New Orleans, LA

Mark Packer MD, Chief Medical Officer will highlight Cassini as core technology in today’s refractive cataract surgery ecosystem. Cassini enables seamless integration of clinic and operating suite, from preoperative diagnostics through visualization and laser applications to postoperative analysis. Cassini data demonstrate 94.0% reduction of astigmatism to target, 0.50 Diopter or less. These results help increase the adoption of premium cataract surgery and Advanced Technology IOL’s.

May 5, 2016

N E W S  R E L E A S E

The Hague / Burlington May 5, 2016 – Cassini, a pioneer in the development of superior eye diagnostic solutions, will feature today as one of the most promising private companies in the Ophthalmology Innovation Showcase at the OIS@ASCRS meeting, a leading event for industry, venture capitalists and academia.  Cassini will also feature over the weekend at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in New Orleans, LA, with multiple papers and presentations in the scientific program.

Mark Packer, who joined Cassini as Chief Medical Officer in February, will present Cassini as a new standard in refractive cataract surgery.  A recent retrospective study conducted by Elizabeth Yeu, MD (Virginia Eye Consultants, VA) demonstrates that Cassini Total Corneal Astigmatism (TCA) achieves 94.0% accuracy within 0.50 Diopter and 74% accuracy within 0.25 Diopter postoperative manifest refractive cylinder in a series of 50 eyes undergoing toric lens implantation. These results compare favorably with 84.0% and 54.0% calculated for the Barrett toric formula and 79.4% and 50.0% for the Baylor nomogram, respectively.1

Dr. Packer comments “Cassini TCA sets a new standard for toric IOLs by eliminating the guess work from the procedure and substantially reducing the number of post-op surprises. These clinical data confirm that the Cassini color LED ray tracing technology enables surgeons to achieve better outcomes and reduce the need for costly post-op enhancement procedures.”

The company will host an educational event on Sunday May 8th from 5:30 to 6:30 PM at the Hilton New Orleans Riverside, with surgeons Elizabeth Yeu, Dee Stephenson, Denise Visco and Mark Packer. Presentations and discussion will highlight how Cassini TCA enables superior results and increases workflow efficiency while catalyzing greater adoption of premium cataract surgery and Advanced Technology IOL’s.

About Cassini:

Cassini pioneers smart and superior eye diagnosis solutions that are affordable, fast and user-friendly for care providers worldwide to serve their patients best.

Cassini Total Corneal Astigmatism helps cataract surgeons to better understand corneal properties in order to improve outcomes and increase premium patient volume. Cassini offers a full suite of examinations required for toric and multifocal IOL implantation. This includes corneal topography, mesopic and photopic pupillometry as well as full color photography for diagnostic purpose. The technology employs red, green and yellow LEDs that are each positioned in a unique relationship to four of its neighbors, giving each one a ’gps-like’ coordinate. Cassini uses the ray-tracing principle to measure the relative position of each point, using the three different colors as ‘triangulation’ points.

SEE THINGS DIFFERENT
www.cassinitca.com

For more information please contact:
Jeroen Cammeraat, CEO, +31 70 399 31 12 info@i-optics.com

Read the full article here.

article references

1. Yeu E. Cassini TCA outperforms nomogram and calculation based estimates of posterior corneal astigmatism. Published by Cassini.

Mark Packer MD, Chief Medical Officer will highlight Cassini as core technology in today’s refractive cataract surgery ecosystem. Cassini enables seamless integration of clinic and operating suite, from preoperative diagnostics through visualization and laser applications to postoperative analysis. Cassini data demonstrate 94.0% reduction of astigmatism to target, 0.50 Diopter or less. These results help increase the adoption of premium cataract surgery and Advanced Technology IOL’s.